Jiwon Oh, MD, PhD, FRCPC - Moving Toward the Future in MS Management: What's the Latest on BTK Inhibition?

PeerView Neuroscience & Psychiatry CME/CNE/CPE Video Podcast

Go online to PeerView.com/WGE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Bruton tyrosine kinase (BTK) inhibitors may soon augment the current armamentarium of DMTs for MS. Four BTK inhibitors are currently in phase 3 trials, generating great interest due to their capacity to reach therapeutic concentrations in the central nervous system and ability to affect processes mediated by B cells and microglia that contribute to the inflammatory and neurodegenerative processes that drive MS. In this activity, an expert reviews the rationale for and shares the latest findings on the efficacy, safety, and tolerability of this promising line of treatment. Upon completion of this activity, participants should be better able to: Explain the rationale for inhibiting BTK to treat MS; Evaluate the current evidence regarding the efficacy, safety, and tolerability of BTK inhibitors being studied for the treatment of MS; and Identify patients who may benefit by treatment with BTK inhibitors, based on current evidence and individual treatment needs and priorities.